Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study
Open accessThe DOI matches its Crossref record; 54 of the 58 references it cites were found in a registry or an index.
Abstract
Background: Identifying reliable predictors of long-term weight loss (LTWL) could lead to improved weight management. Objective: To identify some predictors of LTWL. Design: The DPP (Diabetes Prevention Program) was a randomized controlled trial that compared weight loss with metformin, intensive lifestyle intervention (ILS), or placebo. Its Outcomes Study (DPPOS) observed patients after the masked treatment phase ended. (ClinicalTrials.gov: NCT00004992 and NCT00038727). Setting: 27 DPP and DPPOS clinics. Participants: Of the 3234 randomly assigned participants, 1066 lost at least 5% of baseline weight in the first year and were followed for 15 years. Measurements: Treatment assignment, personal characteristics, and weight. Results: After 1 year, 289 (28.5%) participants in the metformin group, 640 (62.6%) in the ILS group, and 137 (13.4%) in the placebo group had lost at least 5% of their weight. After the masked treatment phase ended, the mean weight loss relative to baseline that was maintained between years 6 and 15 was 6.2% (95% CI, 5.2% to 7.2%) in the metformin group, 3.7% (CI, 3.1% to 4.4%) in the ILS group, and 2.8% (CI, 1.3% to 4.4%) in the placebo group. Independent predictors of LTWL included greater weight loss in the first year in all groups, older age and continued metformin use in the metformin group, older age and absence of either diabetes or a family history of diabetes in the ILS group, and higher fasting plasma glucose levels at baseline in the placebo group. Limitation: Post hoc analysis; examination of nonrandomized subsets of randomized groups after year 1. Conclusion: Among persons with weight loss of at least 5% after 1 year, those originally randomly assigned to metformin had the greatest loss during years 6 to 15. Older age and the amount of weight initially lost were the most consistent predictors of LTWL maintenance. Primary Funding Source: National Institutes of Health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mean weight loss at 15-year follow-up was 6.2% (95% CI, 5.2%-7.2%) for metformin, 3.7% (95% CI, 3.1%-4.4%) for intensive lifestyle intervention, and 2.8% for placebo (95% CI, 1.3%-4.4%).93”
From Obesity Management in Adults: A Review (2023) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Doses of metformin greater than 1500 mg are associated with the greatest weight loss.93,94”
From Obesity Management in Adults: A Review (2023) · cites this paper as [93]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“12 weeks of treatment with licogliflozin led to a numerically greater reduction in liver lipid content, body weight (4.2 %) and HbA1c (1 %) compared to RCTs with sole SGLT2I treatment (Table 1) [161,163].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [161]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 3×
“Randomized controlled trials (RCTs) have shown efficacy of metformin, intensive lifestyle intervention (ILS), or both in preventing or delaying onset of T2D among high-risk persons with overweight and obesity (2, 3).”
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Zeger, S. L., & Liang, K.-Y. (1986) · Biometrics · doi:10.2307/2531248 · Cited by 7,764 · cited 1×
“Second, we used GEE models (15, 16) to examine potential predictors of LTWL across all follow-up years.”
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Models for Longitudinal Data: A Generalized Estimating Equation Approach
Zeger, S. L., Liang, K.-Y., & Albert, P. S. (1988) · Biometrics · doi:10.2307/2531734 · Cited by 4,505 · cited 1×
“Second, we used GEE models (15, 16) to examine potential predictors of LTWL across all follow-up years.”
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
The mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287 · cited 1×
“Its beneficial effects include inhibition of gluconeogenesis with a consequent decrease in hepatic glucose output and increased insulin sensitivity, increased glucose utilization in the gut and enhanced insulin sensitivity in skeletal muscle (25, 26), and effects on the gut microbiota and the immune system (27).”
Changes in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012
The Diabetes Prevention Program (DPP)
The Diabetes Prevention Program (DPP) Research Group (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2165 · Cited by 1,938
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915 · cited 1×
“In the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) trial (20) of 3305 patients with obesity and diabetes, orlistat was associated with weight loss of 9.”
Long-term persistence of hormonal adaptations to weight loss
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105816 · Cited by 1,449
Effect of weight loss with lifestyle intervention on risk of diabetes
Hamman, R. F., Wing, R. R., Edelstein, S. L., Lachin, J. M., Bray, G. A., Delahanty, L., Hoskin, M., Kriska, A. M., Mayer-Davis, E. J., Pi-Sunyer, X., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0560 · Cited by 1,344
Self-citationElfhag, K., & Rössner, S. (2005) · Obesity Reviews · doi:10.1111/j.1467-789x.2005.00170.x · Cited by 1,343
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148 · cited 2×
“Metformin is not known to significantly alter energy expenditure (25, 32).”
(2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00291-0 · Cited by 1,029
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Self-citationAnorexia of aging: physiologic and pathologic
Morley, J. (1997) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/66.4.760 · Cited by 763
(1999) · Diabetes Care · doi:10.2337/diacare.22.4.623 · Cited by 725
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s008 · Cited by 699
Achieving Weight and Activity Goals Among Diabetes Prevention Program Lifestyle Participants
The Diabetes Prevention Program Research Group (2004) · Obesity Research · doi:10.1038/oby.2004.179 · Cited by 529
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1299 · Cited by 494
Control of Food Intake in Older Men
Roberts, S. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03520200057036 · Cited by 419
Qaseem, A., Humphrey, L. L., Sweet, D. E., Starkey, M., Shekelle, P., & for the Clinical Guidelines Committee of the American College of Physicians* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-3-201202070-00011 · Cited by 400
Ely, E. K., Gruss, S. M., Luman, E. T., Gregg, E. W., Ali, M. K., Nhim, K., Rolka, D. B., & Albright, A. L. (2017) · Diabetes Care · doi:10.2337/dc16-2099 · Cited by 386 · cited 1×
“From a population health perspective, this finding gains importance with increasing dissemination and implementation of DPP-modeled lifestyle programs (50) and reimbursement for such interventions (51, 52).”
Drugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis
Domecq, J. P., Prutsky, G., Leppin, A., Sonbol, M. B., Altayar, O., Undavalli, C., Wang, Z., Elraiyah, T., Brito, J. P., Mauck, K. F., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3421 · Cited by 334
Rosenbaum, M., Hirsch, J., Murphy, E., & Leibel, R. L. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.6.1421 · Cited by 315
Effectiveness of Metformin on Weight Loss in Non-Diabetic Individuals with Obesity
Seifarth, C., Schehler, B., & Schneider, H. (2012) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0032-1327734 · Cited by 258
The Diabetes Prevention Program Research Group (2003) · Diabetes Care · doi:10.2337/diacare.26.4.977 · Cited by 218
Psychological and Behavioral Correlates of Baseline BMI in the Diabetes Prevention Program (DPP)
Delahanty, L. M., Meigs, J. B., Hayden, D., Williamson, D. A., Nathan, D. M., & the DPP Research Group (2002) · Diabetes Care · doi:10.2337/diacare.25.11.1992 · Cited by 185
Effect of metformin on food intake in obese subjects
Paolisso, Amato, Eccellente, Gambardella, Tagliamonte, Varricchio, Carella, Giugliano, & D'onofrio (1998) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1998.00304.x · Cited by 142
Long-term persistence with orlistat and sibutramine in a population-based cohort
Padwal, R. S., Kezouh, A., Levine, M. N., & Etminan, M. (2007) · International Journal of Obesity · doi:10.1038/sj.ijo.0803631 · Cited by 125 · cited 1×
“In addition, long-term adherence to orlistat is poor (21).”
Lachin, J. M., Christophi, C. A., Edelstein, S. L., Ehrmann, D. A., Hamman, R. F., Kahn, S. E., Knowler, W. C., Nathan, D. M., & on behalf of the DPP Research Group (2007) · Diabetes · doi:10.2337/db06-0918 · Cited by 107
Self-citationThe effects of metformin on gut microbiota and the immune system as research frontiers
Pollak, M. (2017) · Diabetologia · doi:10.1007/s00125-017-4352-x · Cited by 98 · cited 1×
“Its beneficial effects include inhibition of gluconeogenesis with a consequent decrease in hepatic glucose output and increased insulin sensitivity, increased glucose utilization in the gut and enhanced insulin sensitivity in skeletal muscle (25, 26), and effects on the gut microbiota and the immune system (27).”
The Diabetes Prevention Program Research Group, Venditti, E. M., Bray, G. A., Carrion-Petersen, M. L., Delahanty, L. M., Edelstein, S. L., Hamman, R. F., Hoskin, M. A., Knowler, W. C., & Ma., Y. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.134 · Cited by 93 · cited 1×
“Rates of attendance at 1 or more sessions varied by group (58% in the metformin group, 40% in the ILS group, and 57% in the placebo group) (13).”
Self-citationMoriguti, J. C., Das, S. K., Saltzman, E., Corrales, A., McCrory, M. A., Greenberg, A. S., & Roberts, S. B. (2000) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/55.12.b580 · Cited by 83
Modulation of Hunger by Plasma Glucose and Metformin
Schultes, B., Oltmanns, K. M., Kern, W., Fehm, H. L., Born, J., & Peters, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021450 · Cited by 81
Das, S. K., Moriguti, J. C., McCrory, M. A., Saltzman, E. J., Mosunic, C. J., Greenberg, A. S., & Roberts, S. B. (2001) · Journal of Nutrition · doi:10.1093/jn/131.6.1833 · Cited by 65
Pharmacotherapy for Patients with Obesity
Gadde, K. M., Apolzan, J. W., & Berthoud, H.-R. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.272815 · Cited by 57
Self-citationWilliamson, D. A. (2017) · Obesity · doi:10.1002/oby.21914 · Cited by 56 · cited 1×
“From a population health perspective, this finding gains importance with increasing dissemination and implementation of DPP-modeled lifestyle programs (50) and reimbursement for such interventions (51, 52).”
Greater weight loss with increasing age in the weight loss maintenance trial
Svetkey, L. P., Clark, J. M., Funk, K., Corsino, L., Batch, B. C., Hollis, J. F., Appel, L. J., Brantley, P. J., Loria, C. M., Champagne, C. M., et al. (2014) · Obesity · doi:10.1002/oby.20506 · Cited by 53
Unick, J. L., Pellegrini, C. A., Demos, K. E., & Dorfman, L. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0904-1 · Cited by 43
Differential Neuropeptide Responses to Starvation with Ageing
Kaneda, T., Makino, S., Nishiyama, M., Asaba, K., & Hashimoto, K. (2001) · Journal of Neuroendocrinology · doi:10.1046/j.1365-2826.2001.00730.x · Cited by 37
Modeling Correlated Binary Outcomes with Time-Dependent Covariates
Lalonde, T. L., Nguyen, A. Q., Yin, J., Irimata, K. M., & Wilson, J. R. (2021) · Journal of Data Science · doi:10.6339/jds.2013.11(4).1195 · Cited by 32 · cited 1×
“The GEE models provided an average estimate of the effect of the predictor on LTWL over the course of the study (SAS Proc GENMOD) and used a logit link and an independent correlation to ensure proper parameter estimation (17).”
Berger, S. E., Huggins, G. S., McCaffery, J. M., & Lichtenstein, A. H. (2017) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.117.157446 · Cited by 25
Proportional Feedback Control of Energy Intake During Obesity Pharmacotherapy
Hall, K. D., Sanghvi, A., & Göbel, B. (2017) · Obesity · doi:10.1002/oby.21978 · Cited by 23
Energy expenditure in non-insulin dependent diabetic subjects on metformin or sulphonylurea therapy
Leslie, P., Jung, R. T., Isles, T. E., & Baty, J. (1987) · Clinical Science · doi:10.1042/cs0730041 · Cited by 21 · cited 1×
“Metformin is not known to significantly alter energy expenditure (25, 32).”
on behalf of the Society of Behavioral Medicine Public Policy Leadership Group, Pagoto, S., Pbert, L. A., & Emmons, K. M. (2012) · Translational Behavioral Medicine · doi:10.1007/s13142-012-0168-x · Cited by 16 · cited 1×
“From a population health perspective, this finding gains importance with increasing dissemination and implementation of DPP-modeled lifestyle programs (50) and reimbursement for such interventions (51, 52).”
Funk, L. M., Grubber, J. M., McVay, M. A., Olsen, M. K., Yancy, W. S., & Voils, C. I. (2017) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-017-0425-6 · Cited by 15
Neurochemical Alterations During Age‐Related Anorexia
Blanton, C. A., Horwitz, B. A., & McDonald, R. B. (1999) · Proceedings of The Society for Experimental Biology and Medicine · doi:10.1046/j.1525-1373.1999.d01-70.x · Cited by 12
Out, M., Miedema, I., Jager‐Wittenaar, H., van der Schans, C. P., Krijnen, W. P., Lehert, P., Stehouwer, C. D. A., & Kooy, A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13054 · Cited by 12 · cited 1×
“Decreases in appetite and food intake have been reported with metformin in several (22, 28–30) but not all (31) studies.”
Research works printed but not linked: 2
- 2000, The Diabetes Prevention Program Research Group. Diabetes Care, 23, 1619
- Blanton CA, 1999, Proc Soc Exp Biol Med, 221, 153
Cited by
Obesity Management in Adults: A Review
Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., Nicklas, J. M., Gudzune, K. A., & Jay, M. (2023) · JAMA · doi:10.1001/jama.2023.19897 · Cited by 813
Type 2 diabetes mellitus in older adults: clinical considerations and management
Bellary, S., Kyrou, I., Brown, J. E., & Bailey, C. J. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00512-2 · Cited by 639
GDF15 mediates the effects of metformin on body weight and energy balance
Coll, A. P., Chen, M., Taskar, P., Rimmington, D., Patel, S., Tadross, J. A., Cimino, I., Yang, M., Welsh, P., Virtue, S., et al. (2020) · Nature · doi:10.1038/s41586-019-1911-y · Cited by 584
Chung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., et al. (2020) · Diabetes Care · doi:10.2337/dci20-0022 · Cited by 400
Self-citationSarcopenic obesity: Emerging mechanisms and therapeutic potential
Axelrod, C. L., Dantas, W. S., & Kirwan, J. P. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155639 · Cited by 204
“Metformin attenuates weight gain and results in modest weight reduction over long term administration in humans by restricting food intake and enhancing peripheral insulin sensitivity [130,131].”
Background
Metadata
- Authors
- Apolzan, J. W., Venditti, E. M., Edelstein, S. L., Knowler, W. C., Dabelea, D., Boyko, E. J., Pi-Sunyer, X., Kalyani, R. R., Franks, P. W., Srikanthan, P., Gadde, K. M., & for the Diabetes Prevention Program Research Group*
- Affiliations
- Pennington Biomedical Research Center (US)
- University of Pittsburgh Medical Center (US)
- George Washington University (US)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- Colorado School of Public Health (US)
- VA Puget Sound Health Care System (US)
- Columbia University College of Physicians and Surgeons, New York, New York (X.P.)
- Johns Hopkins University (US)
- Lund University (SE)
- University of California, Los Angeles (US)
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2019-05-21
- Volume
- 170
- Issue
- 10
- Pages
- 682-690
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- PMC
- PMC6829283
- OpenAlex
- W2942237347
- Semantic Scholar
- e07c5f43b88902ef91823985e00f3f37893ea00e
- Cited by
- 156
- References
- 58
- Citations by year
- 2026: 19 · 2025: 20 · 2024: 21 · 2023: 28 · 2022: 22 · 2021: 21 · 2020: 16 · 2019: 9
- FWCI
- 13.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK048489)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- long-term weight loss, metformin, intensive lifestyle intervention, prediabetes, type 2 diabetes prevention, fasting blood glucose, age, family history of diabetes, Diabetes Prevention Program Outcomes Study
- MeSH terms
- Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Life Style, Male, Metformin, Middle Aged, United States, Weight Loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.